
Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.
Ghassan K. Abou-Alfa, MD, reports on data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting regarding final results from the ClarIDHy trial. In the phase 3 study, investigators examined ivosidenib vs placebo in patients with previously treated cholangiocarcinoma and an isocitrate dehydrogenase 1 mutation.
Ghassan K. Abou-Alfa, MD, discusses data from the following presentation: “Final results from ClarIDHy [




